ECCO guidelines on therapeutics in Crohn's disease: Medical treatment

Torres, J. ; Bonovas, S. ; Doherty, G. ; Kucharzik, T. ; Gisbert, J.P. ; Raine, T. ; Adamina, M. ; Armuzzi, A. ; Bachmann, O. ; Bager, P. ; Biancone, L. ; Bokemeyer, B. ; Bossuyt, P. ; Burisch, J. ; Collins, P. ; El-Hussuna, A. ; Ellul, P. ; Frei-Lanter, C. ; Furfaro, F. ; Gingert, C. ; Gionchetti, P. ; Gomollon, F. (Universidad de Zaragoza) ; González-Lorenzo, M. ; Gordon, H. ; Hlavaty, T. ; Juillerat, P. ; Katsanos, K. ; Kopylov, U. ; Krustins, E. ; Lytras, T. ; Maaser, C. ; Magro, F. ; Kenneth Marshall, J. ; Myrelid, P. ; Pellino, G. ; Rosa, I. ; Sabino, J. ; Savarino, E. ; Spinelli, A. ; Stassen, L. ; Uzzan, M. ; Vavricka, S. ; Verstockt, B. ; Warusavitarne, J. ; Zmora, O. ; Fiorino, G. ; on, behalf, of, the, European, Crohn''s, and, Colitis, Organisation, [ECCO]

Resumen: Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability1. CD can affect individuals of any age, from children to the elderly, 2, 3 and may cause significant morbidity and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or abscesses] at diagnosis4. Most patients over time will develop a complication, with roughly 50% of patients requiring surgery within 10 years of diagnosis5-7. As the precise aetiology of CD remains unknown, a curative therapy is not yet available8. Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], locally active steroids [such as budesonide], systemic steroids, thiopurines such as azathioprine [AZA] and mercaptopurine [MP], methotrexate [MTX], and biological therapies [such as anti-TNF, anti-integrins, and anti-IL12/23].
The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines aimed at providing evidence-based guidance on critical aspects of IBD care to all healthcare professionals who manage patients with IBD. To provide high-quality evidence-based recommendations on medical and surgical treatment in CD, ECCO decided to develop these guidelines by adopting the GRADE [Grading of Recommendations Assessment, Development, and Evaluation] approach9. GRADE is a systematic process for developing guidelines that addresses how to frame the healthcare questions, summarize the evidence, ..

Idioma: Inglés

DOI: 10.1093/ecco-jcc/jjz180

Año: 2020

Publicado en: Journal of Crohn's & colitis 14, 1 (2020), 4-22
ISSN: 1873-9946

Factor impacto JCR: 9.071 (2020)

Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 14 / 92 = 0.152 (2020) - Q1 - T1

Factor impacto SCIMAGO: 3.277 - Medicine (miscellaneous) (Q1) - Gastroenterology (Q1)

Tipo y forma: Revisión (PostPrint)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)